Document Detail


Circulating cycloxygenase-2 in patients with tobacco-related intraoral squamous cell carcinoma and evaluation of its peptide inhibitors as potential antitumor agent.
MedLine Citation:
PMID:  20213098     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
PURPOSE: The aim of this study was to quantitate circulating COX-2 levels in patients with tobacco-related intraoral cancer and to evaluate antitumor activities of COX-2 peptide inhibitors in vitro on KB cell lines.
PATIENTS AND METHODS: We used a novel biosensor-based surface plasmon resonance (SPR) technique for estimation of circulating COX-2 levels in 76 patients with oral cancer and 43 normal individuals. Antitumor activities of five COX-2 inhibitory peptides were evaluated using propidium iodide labeling and flow cytometry, alamar blue, MTS, and annexin-V binding assays.
RESULTS: Patients with oral cancer showed threefold increase in serum COX-2 level when compared to normal controls (P < 0.0001). Further, late-stage tumors and lymph node metastasis were associated with significant increase in serum COX-2 levels. Patients with higher circulating COX-2 also showed higher immunoreactivity to anti-COX-2 antibody in the lesions. The peptides significantly reduced viability and inhibited growth/proliferation, induced cytotoxicity and apoptosis in tumor cells. However, no such effect was observed either on normal human leukocytes or on MCF-7 cell line that did not over express COX-2.
CONCLUSION: Our results indicate that SPR may be a useful proteomic technique for quantitative assessment of COX-2 and to identify patients with high-risk oral premalignant or occult cancer, as well as in monitoring response to novel COX-2 targeting strategies. Furthermore, COX-2 peptide inhibitors appear to be a new class of potent anticancer agent for human oral carcinoma.
Authors:
Vaishali Kapoor; Abhay K Singh; Sharmistha Dey; Suresh C Sharma; Satya N Das
Related Documents :
15623598 - Matrix metalloproteinase/tissue inhibitors of matrix metalloproteinase phenotype identi...
17007818 - Pharmacological inhibition of poly(adp-ribose) polymerase inhibits angiogenesis.
12431818 - Angiogenesis in prostate cancer: its role in disease progression and possible therapeut...
11900248 - Colorectal cancer prevention and treatment by inhibition of cyclooxygenase-2.
18723368 - Optimizing treatment for men with advanced prostate cancer: expert recommendations and ...
11267858 - Prognostic importance of the soluble plasminogen activator receptor, supar, in plasma f...
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't     Date:  2010-03-06
Journal Detail:
Title:  Journal of cancer research and clinical oncology     Volume:  136     ISSN:  1432-1335     ISO Abbreviation:  J. Cancer Res. Clin. Oncol.     Publication Date:  2010 Dec 
Date Detail:
Created Date:  2010-10-25     Completed Date:  2010-11-24     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  7902060     Medline TA:  J Cancer Res Clin Oncol     Country:  Germany    
Other Details:
Languages:  eng     Pagination:  1795-804     Citation Subset:  IM    
Affiliation:
Tumor Biology and Molecular Immunology Laboratory, Department of Biotechnology, All India Institute of Medical Sciences, Ansari Nagar, New Delhi 110029, India.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adult
Aged
Antineoplastic Agents / chemical synthesis,  pharmacology
Apoptosis / drug effects
Carcinoma, Squamous Cell / enzymology*,  etiology,  prevention & control
Cell Line, Tumor
Cell Proliferation / drug effects
Cell Survival / drug effects
Cyclooxygenase 2 / blood,  metabolism*
Cyclooxygenase Inhibitors / chemical synthesis,  pharmacology
Female
Flow Cytometry
Humans
Immunohistochemistry
Lymphatic Metastasis
Male
Middle Aged
Mouth Neoplasms / enzymology*,  etiology,  prevention & control
Neoplasm Staging
Peptides / chemical synthesis,  pharmacology*
Smoking / adverse effects
Surface Plasmon Resonance
Young Adult
Chemical
Reg. No./Substance:
0/Antineoplastic Agents; 0/Cyclooxygenase Inhibitors; 0/Peptides; EC 1.14.99.1/Cyclooxygenase 2

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  DNA methylation and carcinogenesis of PRDM5 in cervical cancer.
Next Document:  Clinical investigation of malignant mesothelioma in Japan.